GTS has joined ICG’s technical committee (TC12) for pharmaceutical packaging, aimed at sharing aimed at working collaboratively to increase understanding and standards and, ultimately, prevent the ‘phenomena’ of glass surface delamination.
Glass Technology Services Ltd. (GTS) has joined the International Commission on Glass’ (ICG) technical committee (TC12) for pharmaceutical packaging.
The aim is to share knowledge and experience in dealing with a wide range of pharmaceutical glassware, and exchange understanding and skills with a wider group of peers and technical experts.
The overall aim of the technical committee is to work collaboratively to increase understanding and standards and, ultimately, prevent the ‘phenomena’ of glass surface delamination.
This move builds upon GTS’ existing knowledge and consultancy services, which already sees them working across a wide range of clients operating throughout the pharmaceutical supply-chain, from glass manufacturers to those developing, manufacturing, filling or processing the finished dosage form (FDF) products.
The GTS laboratory already provides a range of related services – including pharmacopoeia standards verification, quality assessment, mechanical performance testing, expert analysis of foreign bodies, defects and surface contaminants, technical failure analysis and a range of delamination services.
Daniel Capon, Laboratory Manager at GTS said: “We are proud to be working with a consortium of esteemed technical experts to further understanding, analysis and control of pharmaceutical packaging defects across the supply-chain.
“The objectives of this technical committee are well aligned with a range of work already underway in our laboratories, so it was a logical move for our nominated expert to join the group to share our experiences as well as expand our own understanding.”
Senior Technologist, Amy Meysner, who takes a lead on chemical migration, durability and delamination analysis in the GTS laboratory, is the nominated expert joining TC12 to represent GTS.
Previously provided as an ad-hoc consultancy service, GTS formalised its delamination services in 2013 in line with the adoption of the United States Pharmacopoeia (USP) chapter <1660> – providing pharmaceutical clients clear options for assessing delamination probability.
These include both analysing suspected cases and a number of delamination study options.
Initial screening is provided to help with the selection of packaging for specific drug products, including how primary packaging resists delamination and the migration of major constituent ions into drug products or supporting solutions.
In addition, long-term exposure scenarios, accelerated attacks and formal propensity studies are all available, providing scientific data and technical reports to support companies in their formal drug application and approval processes.